Healthcare services is the sector every family office says it understands — and the one most offices still under-source. The market is vast, fragmented, and noisy: thousands of founder-owned clinics, labs, and specialty groups that have never seen a structured process, sitting in a category where demand is underwritten by demographics rather than cycle. The opportunity is real. So is the trap — treating “healthcare” as a single lane, accepting brokered volume, and mistaking reimbursement-exposed assets for bargains.
The timing has improved. After a frothy 2024, healthcare-services multiples have reset — a 2025 median near 11.5x EV/EBITDA against roughly 14.5x the year before. Entry discipline is rewarded again. For patient, control-oriented capital, the question is not whether to look at the sector, but which deal avenues actually reward discretion, succession patience, and a multi-decade hold.
The deal avenues that matter
Meridian’s healthcare desk is built around eight recurring situation types — not a database category, but origination lanes where family capital has a structural edge:
- Founder succession. A retiring clinician or operator-founder choosing a steward over the highest bid. Continuity, culture, and trust are priced in — family capital wins against sharper-elbowed sponsors.
- Control platform build. The first institutional cheque into a regional specialty group with add-on density and room to professionalise without stripping clinical autonomy.
- Corporate carve-out. Ambulatory, diagnostic, or outpatient assets inside a larger health system — often mis-valued on a consolidated balance sheet until a buyer speaks directly to the operator.
- Cash-pay specialty roll-up. Ophthalmology, dermatology, med-aesthetics, fertility — categories insulated from reimbursement compression and willing to reward operational patience.
- Diagnostics consolidation. Regional lab and imaging networks where rising validation and quality-system costs push sub-scale operators toward sale conversations.
- Home and behavioral care. Demographically supported platforms — screened hard on payer mix, workforce retention, and regulatory standing.
- Dental platform reset. A crowded sponsor market where multiples have normalised; the edge is succession timing and seller psychology, not auction heat.
- Cross-border corridor. Gulf and Asian family capital meeting Western operator assets — co-invest, carve-out, or bring operating expertise onshore.
Operators the desk has sourced
Meridian’s healthcare work spans listed carve-outs, regional platforms, and cross-border co-investments — the calibre of operator matters as much as the thesis. Representative names surfaced to principals include those below; situation briefs sit on mandate studies.
Deal avenues, indicative economics, and principal memo excerpts are permissioned on request — not published on the homepage.
Where family capital wins — and where it does not
Family offices are advantaged where character is the deciding factor: patience, discretion, willingness to back management, and a horizon measured in decades. They are not advantaged in auction heat for the same trophy asset ten sponsors are chasing, or in thin-margin categories where reimbursement risk dominates the return.
- Win: founder-chosen transitions, cash-pay specialties, first institutional rounds, carve-outs where speed and trust matter more than leverage.
- Pass: urgent-care roll-ups with Medicaid exposure, brokered processes with twenty NDAs, “AI healthcare” stories without recurring revenue.
The sub-sector map
These categories are not interchangeable — the work is in the sub-sector, the situation, and the source:
- Ophthalmology & ASC — premium procedures, cash-pay mix, light institutional penetration.
- Dermatology & aesthetics — fragmented, high same-clinic economics, abundant tuck-ins.
- Diagnostics & labs — scale advantages accelerating as compliance costs rise.
- Home & behavioral — demographic tailwind; diligence on workforce and payer concentration.
- Dental — reset multiples; edge in seller psychology and clinical autonomy.
- Fertility & veterinary — recurring or cash-pay demand with premium multiples for quality operators.
The risk that ends most theses
Healthcare services fails in people risk, not market risk. Value walks out the door each evening — clinicians, technicians, and site managers whose retention through transition is the difference between a platform and a stranded asset. Underwrite the people before the multiple. Reimbursement, payer concentration, and regulatory standing matter — but a cheap asset with a broken clinical culture is still an expensive mistake.
The imperative
Move with a lane, not a slogan. The window — fragmentation, succession, and a multiple reset — is open, but quality founder assets do not sit in broker inboxes waiting. The offices that capture this cycle will have a sharp sub-sector view, a documented source trail on every name, and the discipline to pass on the merely cheap in favour of the genuinely scarce.
